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Cardiovascular disease is the leading cause of mortality in the US and in westernized countries with ischemic heart disease
accounting for the majority of these deaths. Paradoxically, the improvements in the medical and surgical treatments of acute
coronary syndrome are leading to an increasing number of “survivors” who are then developing heart failure. Despite considerable
advances in its management, the gold standard for the treatment of end-stage heart failure patients remains heart transplantation.
Nevertheless, this procedure can be offered only to a small percentage of patients who could benefit from a new heart due to the
limited availability of donor organs. The aim of this review is to evaluate the safety and efficacy of innovative approaches in the
diagnosis and treatment of patients refractory to standard medical therapy and excluded from cardiac transplantation lists.
1. Introduction
Cardiovascular disease is the leading cause of mortality in
USA and Western countries with ischemic heart disease
accounting for the majority of these deaths. Paradoxically,
the improvements in the medical and surgical treatment
of acute coronary syndromes are leading to an increasing
number of “survivors” who are then developing heart failure.
Despite considerable advances in the management of heart
failure, the gold standard for the treatment of end-stage heart
failure patients remains heart transplantation. Nevertheless,
this procedure can be offered only to a small percentage of
patientswho could benefit fromanewheart due to the limited
availability of donor organs. In fact, the number of heart
transplants has remained static worldwide and the number of
heart transplants performed each year in theUShas plateaued
at about 2100 for the past few years. Improving awareness of
the very end stages of heart failure is emerging as amajor need
for the clinical community, and implementing best practices
for palliative care is also imperative.
Anumber of innovative approaches are being investigated
on the basis of improved survival and quality of life in patients
refractory to medical therapy and excluded from cardiac
transplantation lists. These procedures include the optimiza-
tion of medical therapy, coronary artery bypass surgery and
valve surgery in high risk patients, ventricular restoration
techniques, and the implantation of ventricular assist devices
as destination therapy or other approaches (such as cardiac
resynchronization therapy) [1]. Future therapies for heart
failure could include new approaches with stem cell therapy,
associatedwith standard revascularization techniques orwith
other procedures such as the implantation of innovative ven-
tricular assist devices, new ventricular restoration techniques,
or new drugs.
The continuous innovations in proteomic technologies
will help pinpoint protein posttranslational modifications
that could help elucidate the transition to heart failure (HF).
This link between biology and technology could greatly assist
in identifying biomarkers with increased specificity as well as
more effective therapies.
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2. Proteomics to Understand Heart Failure
2.1. The Contribution of Proteomics to Our Understanding of
Biological Systems. Nowadays, mass spectrometry (MS) is
used to detect, identify, and quantify a wide array of com-
pounds spanning from small molecules, pharmaceuticals,
metabolites (hence metabolomics), lipids (hence lipidomics),
and peptides and proteins (hence peptidomics and pro-
teomics). In the last four, the “-omics” suffix implies that
hundreds to thousands of compounds can be detected in a
single analysis providing a snapshot of a given metabolome,
lipidome, peptidome, or proteome, respectively. As it is easy
to imagine this capability has enhanced tremendously our
understanding of biological systems. For the sake of brevity
wewill address the contribution of proteomics toHF research
in this section. For the same reason we cannot be exhaustive
and defer to other comprehensive reviews on cardiovascular
proteomics for the interested reader [2].
The proteome was first defined publicly a little over a
decade ago as the “protein complement of the genome” or the
protein make-up that can be identified and quantified from
a given biological sample. As an axiom, proteomics is the
complex of technologies (centered aroundMS) used to study
the proteome. Perhaps the most important contribution of
these technologies tomodernmedicine is the discovery of the
dazzling diversity of protein posttranslational modifications
(PTMs). There are over 400 PTMs, such as phosphorylation,
nitrosylation, acetylation, and methylation, currently listed
in protein databases [3]. The vast majority of PTMs have
an effect on a protein’s life may it be activity, localization,
turnover, and so forth or in other words its function. Post-
translational modifications are the most likely integrators of
the interactions between the phenotype and the environment
due to their dynamic regulation and this new knowledge
has profound implications for biomedicine. For instance,
the sporadic nature of many diseases, such as HF, could be
explained in the light of proteins and their PTMs rather
than the genetic background. In fact, the prediction of a
phenotype solely based on genes is inherently complicated by
the exponential increase in complexity when moving genes
through transcripts tomodified proteins and their complexes.
The realization that PTMs are so abundant in nature is
daunting; however, the technological advances seen in the
last decade let us hope that their mapping is within reach
and that with this information we will have a high-resolution
picture of the molecular phenotype of many diseases in the
near future.
As technologies quickly develop, their potential clinical
applications also multiply. Like the computer industry some
of these technologies, and mainly MS, have now reached a
point where performance has allowed targeting an interme-
diate segment of the users market. That is to say that high-
performance MS instruments which were previously rele-
gated to well-funded and highly specialized research groups
are now slowly becoming accessible to smaller institutions,
including hospitals and clinical labs. The great potentials for
biomarkers discovery and clinical labs analyses are still largely
unmet by the limited knowledge of the scientific and medical
communities.
2.2. A Brief Overview of the Technical Aspects of Proteomics.
Mass spectrometers are classically named after their anatomy
and are composed of a source, one or more analyzers, and
a detector. For instance, a matrix assisted laser desorption
ionization (MALDI) is a type of source, whereas time-of-
flight (TOF) is one of the first used analyzers. The source
is the part of the instrument where analytes (e.g., peptides
and proteins in proteomics) are ionized so that they can
be separated according to their mass (mass/charge or 𝑚/𝑧)
in the analyzer. Most commonly MS are coupled to liquid
chromatography (LC, hence LC-MS). However, MS that are
coupled with an LC typically have different sources than
MALDI (such as Electron Spray Ionization or ESI) and
analyzers (such as quadrupoles or “Q” and ion traps). To
complicate things further, most modern instruments have
multiple analyzers in series (hence Q-trap, Q-TOF, triple-Q,
etc.).These last instruments are also referred to as tandemMS
(or MS/MS) and the advantage of having multiple analyzers
resides in the capability of sequencing a peptide (and often
assigning PTMsunambiguously), with the cost being the time
for acquisition (or analysis). The number of methodological
approaches that have arisen in the last decade is also complex.
They can be broadly divided into protein- and peptide-
centric (or top-down and bottom-up to use a widespread
nomenclature, resp.). The most common approaches are
peptide-centric, which means that proteins are digested into
peptides prior to MS analysis due to the increased stability
of the latters and the fact that they can be measured more
accurately.The separation of proteins prior toMS analysis can
be achieved by polyacrylamide gel electrophoresis (PAGE) or
LC (hence gel-based and gel-free approaches); however, LC
is also used to inject proteins and peptides directly in the
MS. Moreover, other separation techniques such as capillary
electrophoresis (CE) can be also utilized [4]. One of the
typical approaches based on the direct LC-MS analysis of
digested proteomes is commonly known as “shotgun” [5],
as peptides are digested, desalted, and injected into the MS.
When it comes to quantification, two different schools of
thought advocate for label and label-free approaches. In
the former, peptides are chemically derived with various
chemical “tags” prior to MS analysis. These are released in
the MS to work as “reporters” for the quantity of a given
peptide (and therefore protein) [6]. However, due to the
increased reproducibility of separation and MS technologies,
it is now possible to have an accurate quantification also
in absence of reporters (label-free) [4]. Finally, the clinical
relevance of top-down or protein-centric proteomics in
HF research is also rapidly emerging [7]. Peptide-centric
approaches can be utilized for both the “entire” proteome
(proteome-wide) or fractions of it (subproteomes). Indeed
the complexity of biological systems is such that it is hard to
predict when full proteome-wide coverage will be achieved
for complex samples. The detection of peptides in a MS is a
competitive process; therefore the higher the complexity of
the sample, the higher the chance that low-abundant peptides
(proteins) may be missed. For this reason, the enrichment of
specific PTMs (e.g., phosphoproteome [6]) or subproteomes
(e.g., different organelles [8]) greatly enhances sensitivity.
Targeted proteomics or the application of these technologies
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to highly enriched subproteomes (e.g., individual proteins
end, their PTMs, and their complexes) is arguably the best
approach to gain the deepest level of detail. A successful
example of this concept is the crossover of a MS technique
known as multiple reaction monitoring (MRM) from the
pharmaceutical industry to proteomics. Briefly MRM allows
to precisely quantify proteins using the quantity of few
peptide fragments in a tandem MS. The use of isotopically
labeled internal standard enables absolute quantification. As
an example, multiple reaction monitoring was recently used
to accurately quantify the phosphorylation sites (known and
new) of cardiac TnI, one of the gold standard markers to
diagnose cardiac ischemia [9].
2.3. Proteomics to Tackle Emerging Concepts in HF Research.
There has been an increasing consensus on the similari-
ties between well-established organ proteinopathies (such
as Alzheimer’s and Parkinson’s diseases) and HF [10]. This
concept was pioneered a little over ten years ago by Robbins
and colleagues who reported the presence of preamyloid
oligomers (PAOs) similar to those observed in the brains of
Alzheimer’s patients, in cardiac specimens from HF patients
[11]. In the last few years, this concept has been revamped by
several studies. Fewof themost recent ones have conveniently
exploited proteomic technologies [12–14]. Indeed, it is not
surprising that proteomic analysis will assist with elucidating
new mechanisms of proteotoxicity as they happen not only
in the brain but also in other organs, such as the heart.
Of particular interest is the role of protein PTMs [15, 16].
These can be placed both enzymatically (such as phosphory-
lation) or occur as the result of environmental stress (such
as oxidation). The latters are not regulated and therefore
they can accumulate in a pathological fashion [12, 15]. If
protein misfolding is a mechanism which can result in the
uncontrolled accumulation of toxic species in the heart (such
as PAOs), these technologies will greatly help in dissecting
the relative contribution of different PTMs (chemical and
enzymatic) to the etiology of several diseases, including HF.
2.4.What “Lies” Ahead. As new technologies and approaches
become available to the medical community, it is challeng-
ing to remain up-to-date and pick those that will have
a long-lasting impact. In this concluding paragraph three
emerging methodologies which, in our opinion, are likely
to play a major role in the future of clinical proteomics
will be described briefly. The first is mass cytometry, made
possible by the combination of flow cytometry and a TOF
MS. In short this configuration enables to monitor several
different antigens with little to no cross talk in a given
cell subpopulation [17]. The second is MALDI imaging,
combining the capabilities of MALDI-TOF MS with those
of a microscope. Although its spatial resolution at this stage
is limited, the distribution of a given peptide across a tissue
section can be monitored with this approach [18]. Lastly, a
new acquisition in the proteomic field is the possibility of
accurately measuring the level of thousands of proteins at
one time and retaining the capability of reinterrogating the
obtained data with new questions that may arise even after
the study is concluded. This novel approach has profound
implications for clinical studies as it allows the creation of the
in silico version of a proteome and its repeated interrogation.
For example, this is particularly important for studies on
HF due to the limited availability of (control) tissue [19].
The pioneering work of Aebersold and colleagues trans-
ferred the quantitative capability of MRM to proteome-wide
approaches by using new acquisition methods.The increased
speed of acquisition of certain MS configurations combined
with “unbiased” detection approaches (Data Independent
Acquisition or DIA) now permits “scanning” through a
proteome by missing limited information. This information
can be stored in silico and the resulting database can then
be used as a reference to compare several different biological
conditions and track back changes in a quantitative fashion.
Several other applications are underway, including real-time
diagnostics that could be particularly helpful in the operating
room. With all these new technologies and knowledge there
is an emerging need for technical expertise and education
of the scientific community at large. The implementation of
new software and algorithms to handle the amount of data
that are being rapidly generated is an important task for the
bioinformatic community. Lastly, local regulations will have
to quickly adapt to allow the clinical community to translate
efficiently the potential assays provided by these new tools
into clinical practice.
3. Novel Medical Therapies in Heart Failure
3.1. Heart Failure with Reduced Ejection Fraction (HFrEF). In
the past 25 years, there have been substantial improvements
in the treatment of patients with chronic HFrEF. This is
also due to the increased availability of drugs acting on
the renin-angiotensin-aldosterone system (RAAS) and on
the adrenergic systems, such as ACE inhibitors (ACE-Is),
angiotensin receptor blockers (ARBs), beta-blockers (BBs),
and mineralocorticoid receptor antagonist (MRAs), proved
by international randomized trials to be able to modify the
natural history of this syndrome by prolonging survival [20].
Several demonstrations of a class effect of these drugs
have been proven in the past years, and there is now a need for
new drugs targeting different pathological pathways in order
to further improve survival in HF patients. In a recent update
from the European Society of Cardiology (ESC) guidelines on
the management of acute and chronic HF, twomajor changes
in the pharmacological treatment of patients with chronic
HFrEF must be acknowledged:
(i) MRA treatment extension to patients with mild-to-
moderate HFrEF as a consequence of the results of
the EMPHASIS-HF trial (Eplerenone inMild Patients
Hospitalization and Survival Study in HF) [21], which
enrolled 2737 patients aged ≥55 years with New York
Heart Association (NYHA) functional class II symp-
toms and an ejection fraction (EF) <30% (<35% if the
QRS duration was >130ms). In this study, about 27%
of relative risk reduction in cardiovascular death or
HF hospitalization (primary outcome) was achieved
with eplerenone treatment (up to 50mg once daily).
4 BioMed Research International
Table 1: Recent studies in heart failure with reduced ejection fraction.
Study Type Drug/comp. Number of pts/Age Outcome Results
ARS PoC Finerenone (BAY 94-8862)(nonsteroidal MRA) 458/72
Safety and tolerability
in chronic kidney
disease versus
spironolactone
Significantly lower
incidences of hyperkalemia
than spironolactone
ATMOSPHERE Outcome Aliskiren(direct renin inhibitors) 7000
Cardiovascular death
or HF hospitalization
versus enalapril
Ongoing
LEPTH Outcome Riociguat (guanylatecyclase stimulator) 201/59
Change in mean
pulmonary artery
pressure
Not met but improved
stroke volume and cardiac
index and reduced
pulmonary and systemic
vascular resistance
SOCRATES-REDUCED PoC Vericiguat (guanylatecyclase stimulator) 410
Change in
NT-proBNP Ongoing
PARADIGM-HF Outcome
LCZ696 (ARNI,
angiotensin II receptor
blocker and neprilysin
inhibitor)
8442/63
Death from
cardiovascular causes
or a first
hospitalization for
heart failure
LCZ696 was superior to
enalapril in reducing the
risks of death and of
hospitalization for heart
failure
RED-HF Outcome Darbepoetin Alfa 2278/72
Death or
hospitalization in
patients with Hb
(9.0–12.0 g/dL)
Not met but improved
haemoglobin level
FAIR-HF PoC Intravenous iron (ferriccarboxymaltose) 459/67
Self-reported Patient
Global Assessment
and NYHA functional
class
Improvements in 6-minute
walk test and quality of life
assessment
ICHF PoC Intravenous iron (ferriccarboxymaltose)
Improvement in
LVEF Ongoing
MOOD-HF Outcome Escitalopram (serotoninreuptake inhibitor) 700
Death or
hospitalization Ongoing
PoC, proof-of-concept.
These results led to a class IA recommendation for
MRAs in these guidelines.
(ii) The SHIFT trial (Systolic Heart Failure Treatment
with Ivabradine Compared with Placebo Trial) [22]
has demonstrated that the use of ivabradine, a selec-
tive inhibitor of the If current in the sinoatrial
node was associated with a significant reduction in
the primary endpoint (cardiovascular disease related
death or hospitalization for HF), mainly driven by
a decrease in the rate of hospitalization in patients
with NYHA class II or III HFrEF. This result is
particularly relevant because it is the first drug to
prove a clinically relevant result demonstrated in
a randomized clinical trial in HFrEF patients by
acting on pathophysiological systems different from
the RAAS and the adrenergic system. Ivabradine was
approved by the European Medicines Agency in 2012
for chronic HF in patients with elevated heart rates
but at present it is not yet commercialized in the US.
Several new classes of drugs have been proposed or are
under evaluation (Table 1):
(i) Finerenone (BAY 94-8862) is a next-generation nons-
teroidal MRA that has shown improved selectivity for
the mineralocorticoid receptor.
(ii) Aliskiren, a direct renin inhibitor, decreases PRA and
thus may provide a greater RAAS blockade.
(iii) Omapatrilat is a molecule that was both a neprilysin
and an ACE-I and whose development was ter-
minated because of an unacceptable incidence of
angioedema [23].
(iv) Angiotensin receptor neprilysin inhibitors (ARNIs)
are a new class of drugs developed both to block
the RAAS and augment natriuretic peptides by the
combination of an angiotensin II type 1 receptor
blocker and an inhibitor of neprilysin, also known as
neutral endopeptidase, the enzyme which promotes
breakdown of atrial and brain natriuretic peptides
(ANP and BNP, resp.).
(v) Riociguat is a novel soluble guanylate cyclase stimu-
lator, which produces cGMP, the second messenger
of several biologically active molecules such as nitric
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oxide or natriuretic peptides, and may improve cen-
tral and peripheral hemodynamics.
(vi) Darbepoetin Alfa, an erythropoiesis stimulating
agent, and intravenous ironmay improve outcomes in
patients withHF and anemia, a common comorbidity
in HF. Patients experiencing both conditions have a
lower functional capacity, worse quality of life, and
higher rates of hospitalization and death than those
without anemia [24].
(vii) Incretin based therapies have been developed in
recent years to treat type 2 diabetes mellitus (DM).
These agents include glucagon-like peptide-1 (GLP-
1) agonists (exenatide and liraglutide) and dipeptidyl
peptidase-4 inhibitors (sitagliptin, saxagliptin, and
linagliptin). Animal and proof-of-concept clinical
studies have shown cardioprotective effects of these
drugs and potential benefits in patients with HF [25].
However, a large randomized clinical trial (SAVOR)
testing the DPP4 saxagliptin showed a higher rate
of occurrence of HF in patients with type 2 DM at
high risk of CV events [26]. Another trial testing
the DPP4 alogliptin (EXAMINE trial) showed no
beneficial effect of the drug in patients with type 2
DM and a recent ACS [27]. With respect to GLP-
1 agonist, large-scale clinical trials are still ongoing
(EXCEL, ELIXA).
3.2. Heart Failure with Preserved Ejection Fraction (HFpEF).
“No treatment has yet been shown, convincingly, to reduce
morbidity and mortality in patients with HFpEF.” This is the
beginning of the very brief paragraph dedicated to pharma-
cological treatment of HFpEF in the ESC guidelines for the
diagnosis and treatment of acute and chronic HF published
in 2012. There is in fact substantial lack of evidence in the
management of HFpEF patients: many of the treatments that
have shown a benefit in HFrEF have failed to confirm their
positive effects in patients with HFpEF. This is the case of ad
hoc performed trials performed with ACE-I (PEPCHF) [28]
and angiotensin receptor antagonists (CHARM-Preserved
[29] and I-PRESERVE [30]).
Different reasons for the unsuccessful effects of these
medications have been proposed: some were related to the
patients (e.g., lack of specific symptoms with inappropriate
enrollment and no agreement on the threshold of EF for
definition of preserved systolic function), some were related
to the trials (e.g., prolonged recruitment with a high rate of
dropouts), some were related to the disease (e.g., different
stages of disease), and some others were related to the tested
drugs. For other classes of drugs such as BBs, we lack
evidence from clinical trials (because no specific trial has
ever been designed) and data derived from registries are quite
controversial [31].
Since the publication of ESC guidelines, one large out-
come trial (Treatment of PreservedCardiac FunctionHFwith
an Aldosterone Antagonist, TOPCAT) and several proof-of-
concept studies have been published where well accepted
therapies in HFrEF and new therapeutic agents have been
tested (Table 2).
The idea of evaluating the effect of drugs that have
been proved to be of efficacy in patients with HFrEF in the
setting of HFpEF has led to TOPCAT, the first international,
multicenter, and randomized double-blind trial to assess
the effect of spironolactone on clinical outcomes in the
patients with HFpEF. It failed to demonstrate a significant
improvement in the primary outcome, a composite outcome
of cardiovascular mortality, aborted cardiac arrest, or HF
hospitalization. These results were disappointing since the
Aldosterone Receptor Blockade in Diastolic HF, Aldo-DHF
trial had on the contrary given at least in part promising
results. The substantially neutral results of TOPCAT may be
explained by geographical differences in the characteristics
of patients enrolled in some countries in which healthier
patients were included (e.g., patients enrolled in the placebo
group inRussia andGeorgia experienced a significantly lower
incidence of the primary endpoint compared to those in
North or South America, 8.4 versus 31.8%) in which the
treatment could not demonstrate a benefit, probably resulting
in a dilution of the global effect.
These disappointing results have given the impulse
for research in individualizing new therapeutic targets
by exploring different pathophysiological pathways such
as the nitric oxide (NO) myocardial cyclic guanosine
3󸀠,5󸀠-monophosphate-protein kinase-G pathway (NO-
cGMP-PKG). At least some of the beneficial effects induced
by NO and natriuretic peptides are in fact mediated by
stimulation of soluble and membrane-bound guanylate
cyclases, respectively, which produce the second messenger
cGMP. Phosphodiesterase-5 (PDE-5) metabolizes cGMP
and may limit beneficial NO and natriuretic peptide actions
and reduce cGMP-mediated improvements in myocardial
relaxation and hypertrophy reduction. The hypothesis that
the PDE-5 inhibitor sildenafil might have some benefits in
patients with HFpEF was tested in the RELAX trial.
The PARAMOUNT trial targeted this pathway from a
different point of view and tested in patients with HFpEF
LCZ696, a first-in-class ARNI that is a complex molecule
from the combination of the neprilysin inhibitor prodrug
AHU377 and the ARB valsartan. Neprilysin degrades biolog-
ically active natriuretic peptides which, as described above,
stimulate the production of cGMP.
Inflammation seems to have an important role in the
pathophysiology of HFpEF. The D-HART pilot study was
a small double-blind, randomized, placebo-controlled, and
crossover trial that tested anakinra, an interleukin-1 inhibitor,
in patients with HFpEF. Anakinra led to a statistically
significant improvement in the primary endpoint, which was
peak oxygen consumption (+1.2mL/kg/min, 𝑝 = 0.009),
and a significant reduction in plasma C-reactive protein
(CRP) levels (−74%, 𝑝 = 0.006). The reduction in CRP
levels correlated with the improvement in peak oxygen
consumption (𝑅 = −0.60, 𝑝 = 0.002). Impaired relaxation is a
fundamental component of HFpEF and for this reason there
is a strong pathophysiological rationale for the utilization
of a drug like ranolazine in this setting. The RALI-DHF
(RAnoLazIne for the Treatment of Diastolic HF) study was a
prospective, randomized, double-blind, placebo- controlled,
small, and proof-of-concept study.
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4. Surgical Alternatives in the Therapy of
Severe Left Ventricular Dysfunction
4.1. The Role of Coronary Revascularization. The most com-
mon cause of heart failure with severely depressed left
ventricular ejection fraction (LVEF) is ischemic heart disease,
accounting for more than 60% of cases [32]. Ischemic
etiology of left ventricular (LV) systolic dysfunction leads to
significantly higher mortality rates than other etiologies [33].
The explanation of this aggressive course is the well-known
relationship among myocardial ischemia, interstitial fibrosis,
and endothelial dysfunction, often with associated systemic
comorbidities, such as diabetes, which worsen the natural
history.
Observational studies comparing survival in patients
treated surgically versus medically suggested that coronary
artery bypass grafting (CABG) enhances survival in patients
with ischemic cardiomyopathy [34–41]. Significant reduc-
tions from >50% to 10% inmortality have been demonstrated
with surgery if compared with medical therapy.
Results reported from early trials comparing medical
therapy with CABG for the treatment of stable angina have
a limited value in the current era because both surgical
techniques andmedical therapy have significantly and rapidly
improved. Arterial grafts were rarely used in these trials,
and medical therapy largely consisted of only nitrates and
infrequent use of beta-blockers. Finally, patients with severe
LV dysfunction were largely excluded from the enrollment.
However, the Veteran Affairs Cooperative Study of Surgery
[42] and the Coronary Artery Surgery Study [43] demon-
strated a significantly higher survival rate in the patients
with reduced LVEF after CABG in comparison with those
who were randomized to medical therapy. Other studies
confirmed that CABG in patients with severely depressed
LVEF obtained a satisfactory survival rate similar to cardiac
transplantation [44, 45].
Several contemporary trials studying treatments for
ischemic coronary disease that included an intensive medical
therapy, such as the MASS-II (Medicine, Angioplasty, or
Surgery Study) trial and the COURAGE (Clinical Outcomes
Utilizing Revascularization and Aggressive Drug Evaluation)
trial, excluded patients with severe LV dysfunction [46,
47]. The BARI 2D (Bypass Angioplasty Revascularization
Investigation in Type 2 Diabetes) trial included patients with
LV dysfunction but only 17.5% of patients had LVEF <50%
[48]. The ISCHEMIA (International Study of Comparative
Health Effectiveness with Medical and Invasive Approaches)
trial is currently enrolling patients but exclusion criteria
include LVEF <35% [49].
Among 27 randomized controlled trials comparing
CABG and percutaneous coronary intervention (PCI) [50],
most of the patients had preserved LV systolic function (EF
>50%). None of these trials specifically focused on patients
affected by heart failure and/or LV systolic dysfunction. Two
relatively large trials that included patients with depressed
LVEF were BARI (Bypass Angioplasty Revascularization
Investigation) [51], in which 22% of patients enrolled had
LVEF <50%, and AWESOME (Angina with Extremely Seri-
ous Operative Mortality Evaluation) [52], in which 21% had
LVEF <35%. Analyses of this subset of patients from these
trials confirmed no differences in outcome between PCI and
CABG [45, 53]. Moreover, the most recent trials comparing
PCI with CABG failed to provide a clear superiority. The
SYNTAX trial enrolled approximately 2% of patients with
LVEF <30% [54]. The FREEDOM trial [55] reported similar
outcomes with PCI with drug-eluting stents and CABG in
patients with LVEF <40%, but only 2.5% of the patients
were in this prespecified subgroup with depressed LVEF.
Thus, the available data have insufficient statistical power to
adequately compare PCI and CABG in patients with severe
LV dysfunction.
The STICH trial is the only prospective, randomized,
and controlled trial designed to study the role of CABG
in patients with LVEF ≤35%. The aim of this trial was to
test 2 hypotheses among patients with LVEF ≤35% and
CAD amenable to CABG [56]: the comparison between
CABG and medical therapy (MT) alone in 1,212 patients
and the surgical ventricular restoration (SVR) hypothesis
compared CABG with and without SVR in 1,000 patients.
In the intention-to-treat analysis, no significant difference
was observed in the primary outcome of all-cause mortality
between patients randomized to CABG versus MT over a
median follow-up period of 56 months. The CABG group
reported improved rates of death from cardiovascular causes
and lower rates of a combined endpoint of death from any
cause and hospitalization for heart failure, which were sec-
ondary endpoints of the study [56]. Moreover, as-treated and
adjusted analyses to consider patient crossovers suggested an
overall favorable effect of CABG on primary and secondary
outcomes [57, 58]. Final data derived from this trial suggest
that the observed survival benefits of CABG in patients with
severe LV dysfunction are related primarily to factors such
as functional status assessed by a 6min walk and/or the
Kansas City Cardiomyopathy Questionnaire [59] and the
interaction of angiographic severity of CAD, severity of LV
systolic dysfunction, and severity of LV remodeling [60].
Patients with preserved effort tolerance but with multivessel
CAD, lower EF, and higher end-systolic volume index were
most likely to benefit from CABG, particularly with respect
to long-term survival.
4.2. Surgical Ventricular Reconstruction. Changes in LV
structure and function secondary to heart failure include
remodeling of the LV from its normal elliptical shape to
a more spherical shape. These modifications result in a
dysfunctional, less efficient, and low contractile ventricle and
are predictors of worse prognoses. Surgical ventricular recon-
struction (SVR) may potentially reverse this process and
partially restore functional capacity of LV [61–63]. Vincent
Dor described in 1989 a technique of endoventricular circular
patch plasty more commonly known as surgical ventricular
restoration or Dor Procedure [64]. This technique consists
of aneurysm resection with insertion of a circular Dacron
or pericardial patch to reconstruct the ventricle. Surgical
restoration therefore excludes akinetic septal regions of the
LV and restores LV chamber size and shape to more phys-
iologic conditions. Associated CABG showed significantly
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Figure 1: (a) Acorn CorCap Cardiac Support Device. (b) Myosplint system. (c) Parachute ventricular partitioning device.
improved LV function and outcomes at 1 year [65].The bene-
ficial effects of SVRwere further confirmed by the publication
of outcomes of the Reconstructive Endoventricular Surgery
returning Torsion Original Radius Elliptical shape to the LV
(RESTORE) Group. In this study, 1,198 post-MI patients with
HF were treated, showing an overall 30-day survival of 94%
and 5-year survival of 69% [61].
However, it remained uncertain whether SVR combined
with CABG would result in improved outcomes of patients
with ischemic cardiomyopathy compared with CABG alone,
particularly when associated with optimal medical therapy.
This question led to the surgical ventricular reconstruction
arm of the STICH trial [66]. In this arm, patients were
enrolled if they had coronary disease amenable to surgical
revascularization, severe systolic dysfunction with LVEF
≤35%, and significant LV anterior akinesia or dyskinesia
that was amenable to SVR. A total of 1,000 patients were
randomized to CABG alone versus CABG plus SVR. The
primary outcome was a composite of all-cause mortality
and cardiac hospitalization. The study showed no significant
difference between the 2 therapies for the primary outcome
with a median follow-up of 4 years. There were also no
differences between the 2 groups in terms of secondary
endpoints, including repeat hospitalizations, symptoms, or
quality of life [66]. SVR associated with CABG does not
appear to improve quality of life compared with CABG alone
but does increase health care costs [67].
In the last years, several devices designed to restore LV
geometry and decrease wall stress have been evaluated. The
most tested has been the Acorn CorCap Cardiac Support
Device (Acorn Cardiovascular, Inc). This device consists of
a polyester mesh sutured circumferentially around the heart
from the apex to the atrioventricular groove (Figure 1(a)). It
provides circumferential support, decreases LV wall stress,
and avoids progressive chamber dilatation [68].The results of
the pivotal Acorn clinical trial have been already published.
Three hundred patients affected by HF were randomized
to CorCap implantation with mitral surgery versus mitral
surgery alone and to CorCap plus medical therapy versus
medical therapy alone. Totally, 148 patients received CorCap:
they demonstrated that they need less subsequent procedures
(Cardiac Resynchronization Therapy or CRT, CABG, and
repeat mitral surgery), an improvement in NYHA class and
Minnesota Living with Heart Failure score (MLHF), and
favorable echocardiographic reverse remodeling. However,
no improvement in survival could be demonstrated at 1, 3,
or 5 years [69–71].
The Myosplint system utilized three tensioning rods
placed transversely through the left ventricle at the apex, mid,
and base, respectively, secured and tensioned by epicardial
pads. This device was designed to create a bilobular LV cross
section with the aim of reducing the radius of the chamber of
LV and consequently its wall stress (Figure 1(b)). The device
was tested in 21 consecutive patients to demonstrate safety
and feasibility. Whereas the original concept was proven safe
and feasible, the authors concluded that the device did not
address a satisfactory functional mitral regurgitation repair
as the majority of patients who received the Myosplint also
needed mitral valve surgery [72].
Coapsys device consisted of a similar tensioning device
which bisected the heart and was connected by anterior
and posterior epicardial pads. The aim of this device was
to reposition the papillary muscles by being placed at the
level of the mitral subvalvular apparatus and approximating
the ventricular walls. It could be placed through sternotomy
without cardiopulmonary bypass [73]. A large multicenter
randomized study, the Randomized Evaluation of a Surgical
Treatment for Off-Pump Repair of the Mitral Valve (Restor-
MV trial), enrolled patients with CAD and functional MR
to two arms: CABG with MV repair and CABG alone.
The former arm was further randomized to CABG with
traditional annuloplasty versus CABG with Coapsys. The
latter arm, treatedwith CABG alone, was further randomized
to CABG alone versus CABG with Coapsys.
The trial was stopped in advance because the researchers
failed to secure funding for its continuation.Nevertheless, the
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study demonstrated a survival advantage as well as decreased
adverse events at 2 years in patients treated with CABG and
Coapsys compared to those treated with CABG and standard
annuloplasty [74].
The concept of a less invasive procedure to obtain
LV restoration was exploited by the company BioVentrix,
which developed the Less Invasive Ventricular Enhancement
(LIVE) therapy utilizing the Revivent technology. The tech-
nique involves beating heart isolation of scarred and akinetic
myocardium by using the Revivent Myocardial Anchoring
System. This system is then placed by epicardial perforation
of the myocardium and interventricular septum (IVS) at
the borders of the scarred area. The internal anchor is then
inserted inside the RV and anchored at the right ventricular
surface of the IVS. Consequently, the LV lateral and IVS walls
are slowly and completely apposed and the scar is isolated.
Further investigations as to the role of this device are ongoing
in a phase II study.
In 2006, Sharkey and colleagues described a left ventric-
ular apex occluder, named ventricular partitioning device
(VPD) [75]. The system components are three: an access
system, a delivery system, and the VDP. The access system
is comprised of a 14–16 F guide catheter and dilator which
provide access to the apical LV. The catheter is used to
deliver the collapsed VPD through the aortic valve to the
apex of the LV. The delivery system has an inner lumen with
a balloon just proximal to the engagement screw, which is
used to inflate the VPD in order to achieve the anchoring
of its struts against the ventricular walls, ensuring adequate
isolation of the LV apex and stability of the device. The VPD
consists of an expanded polytetrafluoroethylene (ePTFE)
occlusivemembrane associated with a self-expanding Nitinol
frame shaped like an inverted umbrella or parachute with
16 struts. This device separates the enlarged and scarred left
ventricle into two chambers: one dynamic and one static.
The static chamber is the scarred or aneurysmal part of the
LV that is distal to the device hemodynamically isolated by
the occlusive device membrane; the dynamic chamber is
the remaining normal LV (Figure 1(c)). This division causes
regional hemodynamic unloading of the isolated dilated
apical left ventricle, decreasing wall stress in that region.
Moreover, the dynamic LV becomes less voluminous with
partitioning, leading to volume/pressure unloading of the
functioning myocardium [76]. The first human trial with
the Parachute device (CardioKinetix Inc, Menlo Park, CA)
was a single arm, prospective, and nonrandomized mul-
ticenter study that enrolled 39 patients. The primary end
point was technical safety of the device as well as device-
related complications within the first 6 months of follow-
up. Inclusion criteria were anteroapical akinesis from an
anterior myocardial infarction, LVEF of ≤40%, advanced
NYHA class, and stable optimal medical therapy for at least
3months before enrollment. Exclusion criteria were ischemic
CAD requiring revascularization, previous revascularization,
or CRT within 60 days and patients with significant valve
disease. Of the 39 patients, five were thought to have
unsuitable LV anatomy for VPD placement after enrollment.
After this, the protocol was changed to include computed
tomographic (CT) evaluation before enrollment to determine
LV anatomical suitability. VPD was successfully delivered
in 79% of patients initially enrolled and in 91% of patients
in whom it was technically attempted. Overall 6-month
success rate without events related to the device was 74%.
Hemodynamically, despite significant reductions in LV vol-
umes, LVEF and stroke volume index remained unchanged.
Nevertheless, there was a significant decrease in NYHA class,
and there were trends towards improvement inQOLmeasure
and 6MWD, although they were not statistically significant
[77].
Therefore, Parachute has encouraged with widespread
enthusiasm the design of four trials in different stages
of completion: the PARACHUTE Trial cohorts A and B
following 89 patients enrolled, the PARACHUTE US trial
enrolling 20 patients in 8USA institutions, the PARACHUTE
III postmarketing trial in 20 European centers to follow-up
100 patients, and the PARACHUTE IV trial that has begun
patients enrollment in the second quarter of 2012with the aim
to enroll 478 patients across 65 USA institutions.
4.3. Mitral Valve Surgery. Functional mitral regurgitation
(FMR) is a pathological condition resulting from geomet-
rical distortion of the subvalvular apparatus secondary to
LV enlargement and remodeling and due to idiopathic or
ischemic cardiomyopathy [78]. Thus, FMR is not a primary
mitral valve disease but the result of the previouslymentioned
complex remodeling processes of LV; however, its presence
leads to further remodeling [78]. Surgeons have tried in the
last decades to find the specific solutions to this topic with
contradictory results and unresolved answers.
While some studies on FMR correction are ongoing,
to date no data have clearly demonstrated the superiority
of surgery versus optimal medical therapy [78–82]. Results
from the Michigan University study showed that no evident
advantage is obtained by mitral valve (MV) annuloplasty
when compared to optimalmedical therapy in terms of 5-year
event-free survival in patients with mitral regurgitation and
left ventricular systolic dysfunction of any origin; moreover,
the same results were reached comparing optimal medical
therapy to mitral valve annuloplasty for patients with non-
ischemic etiology of FMR and LV dysfunction [83]. Another
study by Kang et al. similarly showed that MV annuloplasty
plus CABG in ischemic cardiomyopathy did not show any 5-
year survival advantage when compared to isolated CABG
alone but carried the weight of a higher operative mortality
due to concomitant mitral surgery [84]. However, the same
study showed a clear advantage by adding MV surgery in
terms of residual mitral regurgitation in the follow-up of
those patients suffering from severe grade of ischemic FMR
[84]. Wong et al. [85] found that mitral annuloplasty in
patients with moderate MR did not improve 1-, 5-, and 10-
year survival but only the corresponding degrees of residual
valvular regurgitation.
Other authors reported similar 5-year survival between
isolated CABG and CABG plus MV surgery despite a signif-
icant lower mitral regurgitation (MR) grade at 1 year and a
trend toward a lowerMR grade at 5 years in the second group
[86]. The same authors confirmed in a propensity-matched
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analysis a similar 1- and 5-year survival and functional class
with both surgical procedures (CABG versus CABG plusMV
repair) but a significant reduction in MR grade at 1 year by
adding MV repair [87].
On the other hand, some literature data support the
benefit of surgery for FMR. Trichon and coworkers analyzed
a wide series of patients with ischemic FMR and found
that PCI, CABG, and CABG plus MV repair all obtained a
3-year survival advantage compared to medical therapy in
this subset of patients [88]. A retrospective study from the
Brigham and Women’s Hospital in Boston recently reported
an improved survival of patients undergoing mitral valve
repair for cardiomyopathy [89]. A recent analysis of more
than 1,200 patients enrolled in the STICH Trial for ischemic
cardiomyopathy demonstrated that concomitant MV repair
in patients with moderate-to-severe FMR who underwent
CABG reduces 30-day mortality compared to either patients
undergoing isolated CABG or those medically treated [90].
Furthermore, these results were confirmed when 5-year
survival was analyzed in the same subgroups of patients
[90]. The recently published results from the RIME trial,
a randomized controlled multicenter study from United
Kingdom, showed that addition of MV surgery to CABG in
the setting of ischemic cardiomyopathy resulted in similar 1-
year survival, rate of hospital admission, and recurrence of
atrial fibrillation; on the other hand, the study demonstrated
greater 1-year improvement in the primary end point of peak
oxygen consumption in the CABG plus MV repair group
compared with the CABG group with a better LV reverse
remodeling and a higher reduction inMRgrade and in serum
BNP values [91].
When nonischemic cardiomyopathy was considered,
despite the absence of randomized controlled trials com-
paring surgery with optimal medical therapy and different
techniques of surgery and despite the lack of data of a clear
survival advantage potentially obtained with the correction
of the functional incompetent mitral valve, recent literature
studies all confirmed the beneficial impact of surgery [92–95].
Finally, percutaneous mitral valve therapies are of partic-
ular interest in patients at high risk for surgical intervention,
including those with secondary MR related to CAD and
heart failure. Promising results have been reported from
Europe in such patients who remain symptomatic despite
optimal medical therapy and CRT [96–98]. Two ongoing
randomized trials of transcatheter valve repair versusmedical
management [99, 100] may clarify whether treating the
mitral valve in addition to optimal medical therapy improves
outcomes of patients with ischemic MR.
5. New System or New Materials Available for
Future Cardiac Assist Devices
The expansion of cardiac transplant centers without any
increase in donor supply led to longer waiting lists and longer
time to transplantation, during which the prolonged benefit
of the LVAD to provide support for over a year became
apparent, although the majority of patients required support
for shorter periods [101]. The overall survival to transplant
after LVAD support has been around 65% during the past
5 years [102]. The next advance was the demonstration
that the LVAD could also double survival as permanent
“destination” therapy in patients not eligible for transplant.
All these devices comehand in handwith a heavymedication,
especially anticoagulants, creating a new weakness. The need
of an external, anticoagulant-free, and ventricular assistance
as a bridge to decision and/or permanent “destination”
therapy is indubitable. A growing number of heart devices
and machines are being used in heart failure treatment [103–
107]. Ventricular assist devices (VADs) aremachines that help
improve pumping. They have gained well-known approval
for use as a bridge to transplant in patients who are on
medications but still have severe symptoms and are awaiting
a donor heart. Nevertheless, more and more doctors are
exploring the possibility that such devices may be adequate
treatments themselves, preventing the need for a transplant
in some patients. Therefore, they may be used as short-
term (less than 1 week) or longer-term support [102, 108–114].
Most of the devices that we are using make an intrusion
in the body and more critically in the heart (Figure 2).
They are in direct contact with blood and need high doses
of anticoagulants to function properly. Recently, we have
studied a revolutionary system that seems to address all
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Figure 3: Four different methods to weave Nitinol. From left to right: (a) Nitinol woven on PTFE with a solid U-shaped structure; (b) Nitinol
woven on Kevlar in a circular manner; (c) Nitinol woven around a carbon-tube structure fixed on a Kevlar envelope; (d) silicon matrix with
carbon tubes and Nitinol weaning weaving.
these drawbacks. The key advantages of this new BiVAD
are the biventricular assistance and its external positioning.
This last point improves first of all the operative ease and
security. Second, there is no direct contact with circulating
blood getting rid of anticoagulants and furthermore it lowers
the probability of rejection. An additional benefit is the
possibility of differential assistance. In other words, this
BiVAD is adjustable to any heart presenting left, right, or
both sided dilatation [111, 112]. The tool mainly involved
in the development of this new assist device is the metal
alloy of nickel and titanium (Ni-Ti) Ninitol, where the two
elements are present in roughly equal amount. Small changes
in composition can significantly impact its properties. This
alloy exhibits two closely related and unique properties: shape
memory and superelasticity [115–118]. Shape Memory Alloys
(SMAs) are a group of metallic materials that demonstrate
the ability to return to some previously defined shape or
size when subjected to the appropriate thermal procedure
[118]. They have an austenitic (“hot”) phase in which the
material is generally stiffer and has a higher yield point,
and a martensitic (“cool”) phase which is less stiff and
has a lower yield strength. In the low temperature, crystal
phase they are generally superelastic. This means they can
be deformed far more than other metals (approx. 10–20
times) of the same general family. They can be formed into
a shape at higher temperature, cooled, and then formed to
a different shape at room temperature. When heated, they
return to the shape they had at the higher temperature. This
may be repeated through several million cycles. There are
several knownmetal combinations that have these properties.
Nickel-Titanium (Ni-Ti or Nitinol) has proven to be the
most flexible and useful SMA in engineering applications
so far. It has greater ductability, more recoverable motion,
excellent corrosion resistance, stable transition temperatures,
high biocompatibility, and the ability to be electrically heated
for shape memory recovery.
Several designs are under study [119–123]. One of them
is based on a configuration where the Nitinol wires could be
weaved on a tissue or a membrane that would be in direct
contact with the heart walls. Besides, the wires deliver the
highest force when weaved with an angle of 20∘ between
each other. There are many ways to arrange a wire with this
angle; one of those was an accordion like structure weaved on
Kevlar or Teflon (polytetrafluoroethylene, PTFE). Another
configuration is to realize a spiraling pattern keeping the
idea of the 20∘ angle. Lastly, another solution is to use a
solid structure surrounding the heart between each ventricle
(Figure 2). Thanks to this carbon structure, the Nitinol
wires can be attached and pulled until they are tightened
around each ventricle. It is now possible to have different
configurations surrounding each ventricle. In addition to
that, two different wire lengths were tried. Either there was a
uniquewire going several times fromone side of the structure
to the other or there were many wires for each come and go
(Figures 3–5).
6. Conclusions
The modern approach to the diagnosis and treatment of
heart failure is multidisciplinary and should be based on a
close collaboration among researchers, clinicians, and car-
diac surgeons, particularly given that mandatory multiorgan
attention is required in these high risk patients.
Future therapies for heart failure could include ventricu-
lar assist devices implantation or ventricular restoration tech-
niques with the aim to obtain a reverse, positive remodeling
in the unloaded heart.
With an expanding “toolbox” of comprehensive basic,
medical, surgical and technological approaches, it is expected
that these novel findings will soon be translated to the clinical
practice. In fact, new therapeutic strategies are desperately
needed by themillions of patients suffering fromheart failure.
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Figure 4: Ventricular “envelope” with a Nitinol woven structure on both sides.
Figure 5: Wires around the ventricle with a slice of PTFE between the wall and the wires.
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